Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study

PHASE2CompletedINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

May 31, 2013

Study Completion Date

June 30, 2013

Conditions
Acute Heart Failure
Interventions
OTHER

Placebo

Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.

DRUG

Nesiritide

"Active Comparator: Low Dose Nesiritide~Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial."

DRUG

Dopamine

Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.

Trial Locations (8)

27705

Duke University Medical Center, Durham

55415

Minnesota Heart Failure Network, Minneapolis

55905

Mayo Clinic, Rochester

77030

Baylor College of Medicine, Houston

84107

University of Utah Health Sciences Center, Murry

02115

Brigham and Women's Hospital, Boston

05401

University of Vermont- Fletcher Allen Health Care, Burlington

H1T- 1C8

Montreal Heart Institute, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Duke University

OTHER

NCT01132846 - Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study | Biotech Hunter | Biotech Hunter